Respiratory and Allergy Clinic, DIMI-Department of Internal Medicine, University of Genoa, IRCCS Aou San Martino, Largo Rosanna Benzi 10, Genoa 1-16132, Italy.
Department of Medicine, Nova Southeastern University, College of Osteopathic Medicine, Davie Florida, USA.
World Allergy Organ J. 2014 Mar 28;7(1):6. doi: 10.1186/1939-4551-7-6.
We have prepared this document, "Sublingual Immunotherapy: World Allergy Organization Position Paper 2013 Update", according to the evidence-based criteria, revising and updating chapters of the originally published paper, "Sublingual Immunotherapy: World Allergy Organization Position Paper 2009", available at http://www.waojournal.org. Namely, these comprise: "Mechanisms of sublingual immunotherapy;" "Clinical efficacy of sublingual immunotherapy" - reporting all the data of all controlled trials published after 2009; "Safety of sublingual immunotherapy" - with the recently published Grading System for adverse reactions; "Impact of sublingual immunotherapy on the natural history of respiratory allergy" - with the relevant evidences published since 2009; "Efficacy of SLIT in children" - with detailed analysis of all the studies; "Definition of SLIT patient selection" - reporting the criteria for eligibility to sublingual immunotherapy; "The future of immunotherapy in the community care setting"; "Methodology of clinical trials according to the current scientific and regulatory standards"; and "Guideline development: from evidence-based medicine to patients' views" - including the evolution of the methods to make clinical recommendations.Additionally, we have added new chapters to cover a few emerging crucial topics: "Practical aspects of schedules and dosages and counseling for adherence" - which is crucial in clinical practice for all treatments; "Perspectives and new approaches" - including recombinant allergens, adjuvants, modified allergens, and the concept of validity of the single products. Furthermore, "Raising public awareness about sublingual immunotherapy", as a need for our patients, and strategies to increase awareness of allergen immunotherapy (AIT) among patients, the medical community, all healthcare stakeholders, and public opinion, are also reported in detail.
我们根据循证标准准备了这份文件,“舌下免疫疗法:世界过敏组织 2013 年立场更新”,修订和更新了最初发表的论文“舌下免疫疗法:世界过敏组织 2009 年立场”的章节,可在 http://www.waojournal.org 上查阅。即:“舌下免疫疗法的机制”;“舌下免疫疗法的临床疗效”——报告了 2009 年后发表的所有对照试验的数据;“舌下免疫疗法的安全性”——采用最近发表的不良反应分级系统;“舌下免疫疗法对呼吸道过敏自然史的影响”——结合了 2009 年后发表的相关证据;“SLIT 在儿童中的疗效”——对所有研究进行了详细分析;“SLIT 患者选择的定义”——报告了舌下免疫疗法的合格标准;“免疫疗法在社区医疗环境中的未来”;“根据当前科学和监管标准进行临床试验的方法”——包括根据循证医学制定临床建议的方法的演变。此外,我们还增加了新的章节,涵盖了一些新兴的关键主题:“方案和剂量的实际问题以及坚持治疗的咨询”——这对所有治疗方法的临床实践都至关重要;“观点和新方法”——包括重组过敏原、佐剂、修饰过敏原和单一产品有效性的概念。此外,“提高公众对舌下免疫疗法的认识”,作为我们患者的需求,以及增加患者、医学界、所有医疗保健利益相关者和公众对过敏原免疫疗法 (AIT) 的认识的策略,也进行了详细报道。